LLY
2025Q3BMOEli Lilly and Company primary · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
Street
Consensus EPS5.89
Consensus rev—
EPS high—
EPS low—
Dispersion—
Analysts—
EPS rev net 7d—
EPS rev net 30d—
Consensus Δ 7d—
Consensus Δ 30d—
Options
Implied move2.2%
IV front—
P/C full—
P/C front—
Features as of2025-10-29
Run-up
Close—
Ret 5d+0.1%
Ret 10d-1.6%
Ret 20d-1.4%
Ret 30d+7.0%
Actual EPS
7.02Beat
Estimated EPS5.89
Actual revenue
17.6B
Surprise %+19.2%
Beat / missBeat
Beat streak 42
Beat streak 82
Reaction
1-day stock reaction+0.8%
Implied vs actual
Implied 2.2%Actual 2.9%
Gap reaction+2.9%
Day result+3.8%
Next-day upYes
Realized / IV1.34×
Post tape
Post 5d+11.0%
Post 10d+21.1%
Post volume6.0M
Vol ×10d2.27×
Vol ×20d2.10×
Post range4.9%